Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of CM518D1 in advanced solid tumors
CTR20252172Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CM518D1 in Nonhematologic neoplasms, sponsored by Keymed Biosciences. Started Jun 2025; status: active.
02
Drugs
CM518D1
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20252172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252172.